Chemed Sees Q4 Revenue Growth Slow to 3.0% After EPS Miss
Chemed Corporation’s Q4 revenue is forecast to rise 3.0% year-on-year, slowing sharply from last year’s 9.2% gain. Last quarter the company posted $624.9 million in revenue, up 3.1% YoY, while missing analysts’ EPS estimates significantly.
1. Earnings Preview
Chemed will report Q4 earnings tomorrow afternoon, with revenue growth expected to slow to 3.0% year-on-year from the 9.2% gain a year ago. Analysts have reconfirmed their revenue estimates over the past month, signaling a steady outlook heading into the release.
2. Last Quarter Performance
In Q3, Chemed posted $624.9 million in revenue, up 3.1% year-on-year, but delivered a significant EPS shortfall relative to analyst estimates. The company has missed revenue targets multiple times over the last two years.
3. Peer Comparisons
Addus HomeCare achieved 25.6% revenue growth in Q4, matching forecasts, while Brookdale reported a 3.4% revenue decline that missed estimates by 1.7%, triggering a 9.7% share price drop. These peer results set a backdrop for Chemed’s upcoming report.
4. Stock Trend and Outlook
Chemed’s shares have risen 6.8% over the past month, outperforming a 3.5% decline across healthcare providers. The average analyst price target stands at $555.50 compared with the current share price of $478.72.